Wells Fargo Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $77.89 +5.21%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Wells Fargo analyst Derek Archila reiterated an Overweight rating and $76.00 price target on BridgeBio Pharma (NASDAQ: BBIO)
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $54.92 yesterday.
You May Also Be Interested In
- BridgeBio Pharma (BBIO) PT Raised to $108 at Canaccord
- Raymond James Double Downgrades Aardvark Therapeutics Inc (AARD) to Market Perform
- Datadog (DDOG) PT Lowered to $245 at Stifel
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
